SLC5A2 and diabetic ketoacidosis: While sodium-glucose cotransporter 2 (SGLT2) inhibitors provide substantial benefits for glycemic control and reduced cardiovascular and renal risks, they are also associated with an increased risk of diabetic ketoacidosis (DKA) because they stimulate lipolysis.